InMed Pharmaceuticals Inc Dossier - Source-backed chat

InMed Pharmaceuticals Inc

INMNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)0.94

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $1.35Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $7.4M

Enterprise Value $2.3M

Shares Outstanding 5.5M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

InMed Pharmaceuticals is undergoing a massive structural transformation. On May 19, 2026, the company announced a definitive merger agreement with privately-held Mentari Therapeutics in an all-stock transaction. Upon closing (expected in H2 2026), the combined entity will operate under the Mentari Therapeutics name, focus exclusively on migraine prevention therapies (MT-001 and MT-002), and trade under a new Nasdaq ticker. Pre-merger InMed shareholders are expected to own only ~1.51% (subject to net cash adjustments, up to 5.51% in some structures) of the combined company, which will be backed by a massive $290 million private placement. Concurrently, InMed is winding down its legacy commercial ingredient business (BayMedica) and seeking partners for its completed Phase 2 epidermolysis bullosa program (INM-755). While the legacy pipeline (INM-901 for Alzheimer's and INM-089 for Dry AMD) has upcoming pre-IND catalysts in late 2026, the extreme dilution and complete pivot to Mentari's migraine assets make INM a 'Hold' as investors await the closing of the merger and the transition to the new corporate structure.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The merger with Mentari fails to close due to regulatory hurdles, shareholder rejection, or failure to satisfy the minimum financing conditions. InMed is left with a rapidly depleting cash balance ($5.2 million as of March 31, 2026) and no active revenue streams following the wind-down of BayMedica, forcing severe dilutive equity raises to fund legacy preclinical programs.

Base CaseCentral scenario

The merger with Mentari Therapeutics closes successfully in the second half of 2026. The combined company secures the $290 million in private placement funding, extending its cash runway through 2028. Legacy InMed shareholders receive their small pro-rata share of the combined entity and potential contingent value rights (CVRs) from legacy assets. The stock trades in line with the pro-forma equity valuation of approximately $421.4 million.

Bull CaseUpside scenario

Successful consummation of the Mentari Therapeutics merger, unlocking a fully funded migraine prevention pipeline with a cash runway extending into 2029 and multiple Phase 1/2a clinical readouts.

Scenarios reflect our research view at the research date.

Key Investment Merits

Transformative merger with Mentari Therapeutics brings in a highly validated migraine pipeline (MT-001 and MT-002) targeting a multi-billion dollar global market.
The transaction is backed by an oversubscribed $290 million private placement from elite healthcare investors, securing a cash runway through 2028.
Legacy shareholders may receive Contingent Value Rights (CVRs) tied to the monetization or out-licensing of InMed's legacy cannabinoid assets.
Regained compliance with Nasdaq's minimum bid price requirement in June 2026, securing short-term listing stability.

Key Investment Risks

Extreme dilution for existing InMed shareholders, who will own only a tiny fraction (estimated 1.51% to 5.51%) of the post-merger combined company.
High execution and integration risk associated with a reverse merger and complete pivot to a new therapeutic focus (migraine prevention).
Legacy operations are being wound down, leaving the company with zero continuing revenue streams prior to the merger closing.
Legacy preclinical assets (INM-901 and INM-089) face high regulatory hurdles at their upcoming late 2026 pre-IND meetings.

Thesis Invalidation Triggers

Termination or failure of the merger agreement with Mentari Therapeutics.
Inability to secure the minimum required pre-closing private placement financing.
Failure to maintain Nasdaq listing requirements prior to the merger consummation.
Severe negative feedback from the FDA during the planned Q3/Q4 2026 pre-IND meetings for INM-901 or INM-089.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.